Biopharma & Life Sciences
MoonLake Immunotherapeutics Executive Compensation (FY25)
MLTX · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025 ◇ Jorge Santos da Silva | Latest say-on-pay support = June 9, 2026 |
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
The paid brief on MoonLake Immunotherapeutics
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Data as of November 5, 2026Latest filing (8-K): June 9, 2026
7 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Velarion Intel, one year, every company
116 figures on this page: 113 cited to the filing that reported them, 3 calculated from figures it prints. See the citations
More on MoonLake Immunotherapeutics
Five data products on this company. Each one is requested through the developer setup page.
- Peer Disclosure Audit$5The comparison companies this board named, each one tied to the filing that lists it.How to get Peer Disclosure Audit
- Governance Provisions PullfreeThe governance provisions as the proxy states them: board leadership, committee membership, and shareholder rights.How to get Governance Provisions Pull
- Say-on-Pay Risk Signal$9A risk band for the next say-on-pay vote, with the support history and the peer comparison behind it.How to get Say-on-Pay Risk Signal
- NEO Comp Report$24Every named executive officer’s pay by element and year, with the citation behind each figure.How to get NEO Comp Report
- Board Comp Report$24What each non-employee director was paid, the standing fee schedule, and the equity each one holds at year end.How to get Board Comp Report
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Jorge Santos da Silva: $1,406,038 → $4,943,209 (251.6% higher)
Frequently asked questions
Answers drawn from the data on this page.
Who is MoonLake Immunotherapeutics' chief executive and what were they paid?
Jorge Santos da Silva, Chief Executive Officer; Interim Chair of the Board, received $4,943,209 in total compensation for fiscal 2025. Santos da Silva's total moved 251.6% higher from the $1,406,038 reported for fiscal 2024.
What was MoonLake Immunotherapeutics' say-on-pay result?
Shareholders supported the say-on-pay proposal with 98.6% of votes cast for or against in favor at the meeting held June 9, 2026 for fiscal 2025.
Which companies are in MoonLake Immunotherapeutics' peer group?
The disclosed peer group includes Bicycle Therapeutics, Immunovant, Protagonist Therapeutics, Summit Therapeutics and Vera Therapeutics.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Matthias Bodenstedt Chief Financial Officer | ◇ | ◇ | ◇ | — | — | ◇ | ◇ | ◇ |
Kristian Reich Chief Scientific Officer | ◇ | ◇ | ◇ | — | — | — | ◇ | ◇ |
Jorge da Silva Chief Executive Officer | ◇ | ◇ | ◇ | — | — | ◇ | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Kristian Reich Chief Scientific Officer | ◇ | ◇ | — | — | — | — | ◇ | ◇ |
Jorge Santos da Silva Chief Executive Officer; Interim Chair of the Board Served on an interim basis | ◇ | ◇ | — | — | — | — | ◇ | ◇ |
Matthias Bodenstedt Chief Financial Officer | ◇ | ◇ | — | — | — | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Jorge Santos da Silva Chief Executive Officer; Interim Chair of the Board Served on an interim basis | ◇ | ◇ | — | — | — | ◇ | ◇ | ◇ |
Kristian Reich Chief Scientific Officer | ◇ | ◇ | — | — | — | — | ◇ | ◇ |
Matthias Bodenstedt Chief Financial Officer | ◇ | ◇ | — | — | — | ◇ | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Jorge Santos da Silva Chief Executive Officer; Interim Chair of the Board Served on an interim basis | ◇ | — | ◇ | — | — | ◇ | ◇ | ◇ |
Kristian Reich Chief Scientific Officer | ◇ | — | — | ◇ | — | — | ◇ | ◇ |
Matthias Bodenstedt Chief Financial Officer | ◇ | — | ◇ | — | — | ◇ | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Dr. Jorge Santos da Silva | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Dr. Kristian Reich | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Matthias Bodenstedt | RSU | ◇ | — | — | ◇ | — | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Kristian Reich | Option | ◇ | — | ◇ | 02/27/2035 |
| RSU | ◇ | ◇ | — | — | |
| Matthias Bodenstedt | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| Jorge Santos da Silva | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Simon Sturge | ◇ | — | ◇ | — | — | — | ◇ |
Dr. Ramnik Xavier | ◇ | — | ◇ | — | — | — | ◇ |
Catherine Moukheibir | ◇ | — | ◇ | — | — | — | ◇ |
Dr. Andrew Phillips | ◇ | — | ◇ | — | — | — | ◇ |
Spike Loy Lead independent director | ◇ | — | ◇ | — | — | — | ◇ |
Dr. Jorge Santos da Silva served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Bicycle Therapeutics BCYC
- Immunovant IMVT
- Protagonist Therapeutics PTGX
- Summit Therapeutics SMMT
- Vera Therapeutics VERA
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 9, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | June 5, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | June 5, 2024 | = | ◇ | ◇ | ◇ |
Ask our research desk — $99, 24h, every figure cited to its filing.
Sample answer — “What is the CEO’s total compensation?”
- Jorge Santos da Silva (Chief Executive Officer; Interim Chair of the Board), FY2025 total compensation $4,943,209 (base salary $762,386) [exec_comp, SEC accession 0001140361-26-015916, filed 2026-04-21]What this page does not include
Everything above is a fact MoonLake Immunotherapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where MoonLake Immunotherapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
116 figures on this page: 113 cited to the filing that reported them, 3 calculated from figures it prints.
113 cited to the filing
3 calculated from the filing
Documents cited
- 0001213900-26-066821Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001140361-26-0159162025 Grants of Plan-Based Awards Table · 2025 Non-Employee Director Compensation · 2025 Summary Compensation Table · Director Compensation · and 2 more sections
- 0001213900-25-052140Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001140361-25-014923Summary Compensation Table
- 0001213900-24-050194Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001140361-24-021744Summary Compensation Table
- 0001140361-23-020595
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “MoonLake Immunotherapeutics executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/MLTX (accessed 2026).
Short form: data: Velarion
The paid brief for MoonLake Immunotherapeutics
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
7 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about MoonLake Immunotherapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Peers MoonLake Immunotherapeutics discloses
The companies named in MLTX's own disclosed peer group.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}